Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Preclinical therapeutic synergy of MEK1/2 and CDK4/6 inhibition in neuroblastoma

Hart, Lori and Rader, JulieAnn and Raman, Pichai and Batra, Vandana and Tsang, Matthew and Gagliardi, Maria and Martinez, Daniel and Wood, Andrew and Kim, Sunkyu and Parasuraman, Sudha and Delach, Scott and Cole, Kristina and Shiva, Krupa and Caponigro, Giordano and Peters, Malte and Boehm, Markus and Maris, John (2017) Preclinical therapeutic synergy of MEK1/2 and CDK4/6 inhibition in neuroblastoma. Clinical Cancer Research, 23 (7). pp. 1785-1796. ISSN 1557-3265

Abstract

Purpose: Neuroblastoma is treated with aggressive multimodal therapy, yet more than 50% of patients experience relapse. We recently showed that relapsed neuroblastomas frequently harbor mutations leading to hyperactivated ERK signaling and sensitivity to MEK inhibition therapy. Here we sought to define a synergistic therapeutic partner to potentiate MEK inhibition. Experimental Design: We first surveyed 22 genetically annotated human neuroblastoma-derived cell lines (from 20 unique patients) for sensitivity to the MEK inhibitor binimetinib. After noting an inverse correlation with sensitivity to ribociclib (CDK4/6 inhibitor), we studied the combinatorial effect of these two agents using proliferation assays, cell-cycle analysis, Ki67 immunostaining, time-lapse microscopy, and xenograft studies. Results: Sensitivity to binimetinib and ribociclib was inversely related (r = -0.58, P = 0.009). MYCN amplification status and expression were associated with ribociclib sensitivity and binimetinib resistance, whereas increased MAPK signaling was the main determinant of binimetinib sensitivity and ribociclib resistance. Treatment with both compounds resulted in synergistic or additive cellular growth inhibition in all lines tested and significant inhibition of tumor growth in three of four xenograft models of neuroblastoma. The augmented growth inhibition was attributed to diminished cell-cycle progression that was reversible upon removal of drugs. Conclusions: Here we demonstrate that combined binimetinib and ribociclib treatment shows therapeutic synergy across a broad panel of high-risk neuroblastoma preclinical models. These data support testing this combination therapy in relapsed highrisk neuroblastoma patients, with focus on cases with hyperactivated RAS-MAPK signaling.

Item Type: Article
Date Deposited: 22 Nov 2017 00:45
Last Modified: 25 Jan 2019 00:45
URI: https://oak.novartis.com/id/eprint/29012

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.